Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EBITDA (2016 - 2025)

Northwest Biotherapeutics' EBITDA history spans 16 years, with the latest figure at $1.5 million for Q4 2025.

  • Quarterly results put EBITDA at $1.5 million for Q4 2025, up 106.07% from a year ago — trailing twelve months through Dec 2025 was -$65.4 million (up 21.8% YoY), and the annual figure for FY2025 was -$65.4 million, up 21.8%.
  • EBITDA for Q4 2025 was $1.5 million at Northwest Biotherapeutics, up from -$26.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $1.5 million in Q4 2025 to a low of -$26.6 million in Q3 2025.
  • The 5-year median for EBITDA is -$18.2 million (2022), against an average of -$16.7 million.
  • The sharpest move saw EBITDA crashed 149.84% in 2021, then skyrocketed 106.07% in 2025.
  • Year by year, EBITDA stood at -$10.7 million in 2021, then crashed by 70.27% to -$18.2 million in 2022, then dropped by 15.6% to -$21.0 million in 2023, then fell by 20.99% to -$25.4 million in 2024, then soared by 106.07% to $1.5 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $1.5 million, -$26.6 million, and -$19.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.